Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats

Kidney International

Volumn 59, Issue 5, 2001, Pages 1899-1910

  Ma, L J ^a   Marcantoni, C ^a   Linton, M F ^a   Fazio, S ^a   Fogo, A B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cell turnover; Macrophage; p21; p27; Plasminogen activator inhibitor 1

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; CREATININE; CYCLINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P21; PROTEIN P27; RESERPINE; TRIACYLGLYCEROL; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; GLOMERULOSCLEROSIS; IN SITU HYBRIDIZATION; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RNA ANALYSIS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035046542     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.0590051899.x     Document Type: Article

References (78)

1. Role of insulin resistance in human disease
2. Hypertension and insulin resistance: Role of peroxisome proliferator-activated receptor gamma
3. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent
4. Characterization of new oral antidiabetic agent CS-045: Studies in KK and ob/ob mice and Zucker fatty rats
5. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone
6. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys
7. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptorgamma reverses the diabetic phenotype of the Zucker diabetic fatty rat
8. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM
9. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM: AD-4833 Glucose Clamp Study Group, Japan
10. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
11. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
12. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones
13. The nuclear receptor superfamily: The second dacade
14. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma
15. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation
16. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs
17. Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene
18. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor
19. Adipocyte differentiation: A transcriptional regulatory cascade
20. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor
21. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans
22. Beyond cholesterol
23. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
24. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ
25. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
26. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression
27. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function
28. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats
29. Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits
30. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat
31. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure
32. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse
33. Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice
34. Type II hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E
35. Plasminogen activator inhibitor-1 (PAI-1) expression is regulated by the angiotensin type 1 receptor in vivo
36. Expression of p21 and p27 cyclin-dependent kinase inhibitors during human hematopoiesis
37. Expression of peroxisome proliferator-activated receptor γ (PPAR γ) in human transitional bladder cancer and its role in inducing cell death
38. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition
39. Regression of sclerosis in aging by angiotensin inhibition-induced decrease in PAI-1
40. Mesangial matrix modulation and glomerulosderosis
41. Progression and potential regression of glomerulosclerosis. (Nephrology Forum)
42. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation
43. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis
44. "Intact nephrons" as the primary origin of proteinuria in chronic renal disease: Study in the rat model of subtotal nephrectomy
45. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis
46. Cause of variable therapeutic efficiency of angiotensin-converting enzyme inhibitor on the glomerular mesangial lesions
47. G1 events and regulation of cell proliferation
48. Cell cycle regulatory proteins in glomerular disease
49. The pathogenesis of atherosclerosis: A perspective for the 1990s
50. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats
51. Peroxisome proliferatoractivated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
52. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
53. Changes in cell-cycle protein expression during experimental mesangial proliferative glomerulonephritis
54. Cyclin kinase inhibitors are increased during experimental membranous nephropathy: Potential role in limiting glomerular epithelial cell proliferation in vivo
55. Inhibiting CDK inhibitors: New lessons from DNA tumor viruses
56. New functional activities for the p21 family of CDK inhibitors
57. Regulation of mesangial proliferation
58. The lack of a functional p21 (WAF1/CIP1) gene ameliorates progression to chronic renal failure
59. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis
60. Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition
61. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus
62. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
63. The peroxisome proliferatoractivated receptor-gamma is a negative regulator of macrophage activation
64. Interaction of AP-1, AP-2 and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response
65. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG 2 cells
66. TGF-β: A cytokine mediator of glomerulosclerosis and a target for therapeutic intervention
67. Suppression of experi mental glomerulonephritis by antiserum against transforming growth factor β1
68. Determinants of focal and segmental glomerulosclerosis in the rat after renal ablation: Evidence for involvement of macrophages and lipids
69. The mesangium in antithy-1 nephritis: Influx of macrophages, mesangial cell hypercellularity, and macromolecular accumulation
70. Glomerular macrophage modulation affects mesangial expansion in the rat after renal ablation
71. Secretory products of macrophages
72. Inhibition of oxidation of low density lipoprotein by troglitazone
73. Role of lipids in the progression of renal disease in chronic renal failure: Evidence from animal studies and pathogenesis
74. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophage by colony stimulating factors and oxidized low density lipoprotein
75. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferatoractivated receptor-gamma activators
76. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
77. Down-regulation of transforming growth factor-β receptors: Cooperativity between the type 1, II, and III receptors and modulation at the cell surface
78. Ligand structure influences autologous downregulation of estrogen receptor-alpha messenger RNA